tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Matthew Sykes, 63 are a HOLD (30.58%), 30 are a SELL (14.56%), 113 are a BUY (54.85%).
Analyst Matthew Sykes, currently employed at GOLDMAN SACHS, carries an average stock price target met ratio of 56.8% that have a potential upside of 19.75% achieved within 92 days.
Matthew Sykes’s has documented 391 price targets and ratings displayed on 35 stocks. The coverage is on Healthcare, Basic Materials sectors.
Most recent stock forecast was given on CDNA, Caredx at 17-Apr-2025.
Analyst best performing recommendations are on ZY (ZYMERGEN).
The best stock recommendation documented was for ZY (ZYMERGEN) at 8/4/2021. The price target of $12 was fulfilled within 1 day with a profit of $3.75 (45.45%) receiving and performance score of 454.55.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$205
$18.17 (9.73%)
$240
15 days ago
(10-Apr-2025)
14/22 (63.64%)
$24.24 (13.41%)
264
Hold
$260
$73.17 (39.16%)
$250
1 months 4 days ago
(21-Mar-2025)
5/7 (71.43%)
$48.64 (23.01%)
157
Hold
$260
$73.17 (39.16%)
$265
1 months 11 days ago
(14-Mar-2025)
7/9 (77.78%)
$49.26 (23.37%)
152
Hold
$275
2 months 22 days ago
(03-Feb-2025)
4/6 (66.67%)
$30.89 (12.65%)
174
Hold
$240
$53.17 (28.46%)
$281
2 months 26 days ago
(30-Jan-2025)
8/11 (72.73%)
$16.92 (7.58%)
434
Which stock is Matthew Sykes is most bullish on?
Which stock is Matthew Sykes is most reserved on?
What Year was the first public recommendation made by Matthew Sykes?
